AVITA Medical Inc
AVH: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$8.90 | Jxs | Mfcdvdmn |
Avita Medical: Slight Downgrade but Long-Term Intact
We decrease our fair value estimate for no-moat Avita Medical by 4% to AUD 5.40. This is largely due to the weaker U.S. dollar. We have also cut our fiscal 2023 revenue forecast by 4% to USD 50 million and now expect a net loss of USD 39 million from a loss of USD 38 million prior. However, we leave our long-term estimates unchanged.